However, despite the proven advantages of ASDs, several short-comings hinder the successful translation of more ASD-based dosage forms to the market. The drug load in stable ASDs is typically low (10 -30 wt%) as it is limited by the drug solubility in the polymer at storage temperature, this in turn means that the size of the dosage form increases when a higher drug dose is required, with negative implications for the patient. Furthermore, many polymers commonly used as ASD excipients, such as polyvinylpyrrolidone (PVP) are hygroscopic. Such excipients increase the molecular mobility in the ASDs due to the plasticizing effect of adsorbed water, and hence, can induce amorphous-amorphous phase separation and ultimately recrystallization of the drug during storage. Finally, amorphous powders exhibit poor flowability in pharmaceutical tableting equipment. As a result, ASD manufacturing requires additional processing steps, such as granulation, which increases the complexity and cost of production.